Curator Dashboard

A publicly accessible web-based database through which the interactions between a variety of chelating groups and various central metal ions in the active site of metalloproteins can be explored in detail. Additional information can also be retrieved including protein and inhibitor names, the amino acid residues coordinated to the central metal ion, and the binding affinity of the inhibitor for the target metalloprotein.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Data set of connection probabilities and PSP amplitudes from Chapeton, J., Fares, T., LaSota, D., and Stepanyants, A., Efficient associative memory storage in cortical circuits of inhibitory and excitatory neurons, PNAS, 109(51): E3614E3622 (2012). Available as a PDF under Resources tab.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

A virtual database currently indexing available cell lines from: Coriell Cell Repositories, International Mouse Strain Resource (IMSR), ATCC, NIH Human Pluripotent Stem Cell Registry, NIGMS Human Genetic Cell Repository, and Developmental Therapeutics Program.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Java library and a web service for extracting metadata and content from scientific articles in born-digital form. The system analyses the entire content of a PDF file containing a publication and attempts to extract information such as: the title of the article, journal information (title, etc.), bibliographic information (volume, issue, page numbers, etc.), authors and affiliations, keywords, abstract, bibliographic references and structured sections hierarchy.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. A software program for mapping and aligning cDNA sequences to a genome. The program maps and aligns a single sequence with minimal startup time and memory requirements, and provides fast batch processing of large sequence sets. The program generates accurate gene structures, even in the presence of substantial polymorphisms and sequence errors, without using probabilistic splice site models. Methodology underlying the program includes a minimal sampling strategy for genomic mapping, oligomer chaining for approximate alignment, sandwich DP for splice site detection, and microexon identification with statistical significance testing.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Data set generated by personal omics profiling of Dr. Michael Snyder at Stanford University. It combines genomic, transcriptomic, proteomic, metabolomic, and autoantibody profiles from a single individual over a 14 month period. The analysis revealed various medical risks, including type II diabetes. It also uncovered extensive, dynamic changes in diverse molecular components and biological pathways across healthy and diseased conditions.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Software application that is a forward-time population simulation method that can simulate realistic patterns of LD in both family-based and case-control datasets. (entry from Genetic Analysis Software)

• Resource
• SciCrunch
• 14 years ago - by Anonymous

An Antibody supplier

• Resource
• SciCrunch
• 14 years ago - by Anonymous

American chemical, life science and biotechnology company owned by Merck KGaA. Merger of Sigma Chemical Company and Aldrich Chemical Company. Provides organic and inorganic chemicals, building blocks, reagents, advanced materials and stable isotopes for chemical synthesis, medicinal chemistry and materials science, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, proteins, peptides, amino acids and their derivatives.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

An Antibody supplier

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Proteintech Europe Ltd is an ISO 9001:2008 certified company

• Resource
• SciCrunch
• 14 years ago - by Anonymous

A research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene''s vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Their flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collection and over 25,000 TrueORF cDNA clones. From their TrueORF cDNA clones, they have developed the largest offering of full length human proteins expressed in mammalian cells, ideal for functional studies. Their TrueMAB project develops mouse monoclonal antibodies against protein antigens with the goal to develop protein assays for every human protein. They also offer complete molecular biology services from codon optimization, gene synthesis, protein expression and assay development. In addition, they offer unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

An Organization portal, Antibody supplier, Service resource,

• Resource
• SciCrunch
• 14 years ago - by Anonymous

An Antibody supplier

• Resource
• SciCrunch
• 14 years ago - by Anonymous

THIS RESOURCE IS NO LONGER IN SERVICE, documented on February 2nd, 2022. Antibody supplier.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

An Antibody supplier

• Resource
• SciCrunch
• 14 years ago - by Anonymous

A tool for finding dbGaP studies containing phenotype variables of interest. Lack of standardization makes locating and categorizing previously measured variables difficult. This query tool for biomedical researchers is to identify studies and phenotype variables of interest.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Portal to resources, expertise, and best practices for investigators, study staff, participants and partners/affiliates to facilitate efficient, compliant and ethical study conduct and management. This collaborative effort across a number of organizations and administrative units was built to leverage existing resources and create new content where readily accessible resources currently don''''t exist. The goals of the HUB are to: * Promote excellence in the quality of clinical research management through education. * Facilitate effective and timely clinical research initiation by improving institutional processes and providing clinical research protocol, regulatory, budget, and financial tools. * Increase awareness of clinical trials in the community through education and community participant recruitment outreach activities. * Interface with institutional/industry partners to support enhanced clinical research practice.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Data repository of de-identified patient data, aggregated in a standardized manner, to enable analyses across many rare diseases and to facilitate various research projects, clinical studies, and clinical trials. The aim is to facilitate drug and therapeutics development, and to improve the quality of life for the many millions of people who are suffering from rare diseases. The goal of GRDR is to enable analyses of data across many rare diseases and to facilitate clinical trials and other studies. During the two-year pilot program, a web-based template will be developed to allow any patient organization to establish a rare disease patient registry. At the conclusion of the program, guidance will be available to patient groups to establish a registry and to contribute de-identified patient data to the GRDR repository. A Request for Information (RFI) was released on February 10, 2012 requesting information from patient groups about their interest in participating in a GRDR pilot project. ORDR selected 30 patient organizations to participate in this pilot program to test the different functionalities of the GRDR. Fifteen (15) organizations with established registries and 15 organizations that do not have patient registry. The 15 patient groups, each without a registry, were selected to assist in testing the implementation of the ORDR Common Data Elements (CDEs) in the newly developed registry infrastructure. These organizations will participate in the development and promotion of a new patient registry for their rare disease. The GRDR program will fund the development and hosting of the registry during the pilot program. Thereafter, the patient registry is expected to be self-sustaining.The 15 established patient registries were selected to integrate their de-identified data into the GRDR to evaluate the data mapping and data import/export processes. The GRDR team will assist these organizations in mapping their existing registry data to the CDEs. Participating registries must have a means to export their de-identified registry data into a specified data format that will facilitate loading the data into the GRDR repository on a regular basis. The GRDR will also develop the capability to link patients'''' data and medical information to donated biospecimens by using a Voluntary Global Unique Patient Identifier (GUID). The identifier will enable the creation of an interface between the patient registries that are linked to biorepositories and the Rare Disease Human Biospecimens/Biorepositories (RD-HUB) http://biospecimens.ordr.info.nih.gov/.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

THIS RESOURCE IS NO LONGER IN SERVICE, documented April 28, 2017. Videos and presentations from the Summer Course Cellular biology of addiction.

• Resource
• SciCrunch
• 14 years ago - by Anonymous